- Home
- AMRC vs OCS Comparison
AMRC vs OCS Comparison
Compare AMRC & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRC
- OCS
- Stock Information
- Founded
- AMRC 2000
- OCS 2003
- Country
- AMRC United States
- OCS Switzerland
- Employees
- AMRC N/A
- OCS N/A
- Industry
- AMRC Engineering & Construction
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- AMRC Consumer Discretionary
- OCS Health Care
- Exchange
- AMRC Nasdaq
- OCS Nasdaq
- Market Cap
- AMRC 1.2B
- OCS 956.4M
- IPO Year
- AMRC 2010
- OCS N/A
- Fundamental
- Price
- AMRC $24.35
- OCS $17.85
- Analyst Decision
- AMRC Buy
- OCS Strong Buy
- Analyst Count
- AMRC 7
- OCS 3
- Target Price
- AMRC $18.57
- OCS $35.67
- AVG Volume (30 Days)
- AMRC 804.4K
- OCS 11.4K
- Earning Date
- AMRC 08-04-2025
- OCS 08-21-2025
- Dividend Yield
- AMRC N/A
- OCS N/A
- EPS Growth
- AMRC 9.21
- OCS N/A
- EPS
- AMRC 1.17
- OCS N/A
- Revenue
- AMRC $1,858,653,000.00
- OCS $960,668.00
- Revenue This Year
- AMRC $8.59
- OCS $11.49
- Revenue Next Year
- AMRC $9.78
- OCS $1,784.02
- P/E Ratio
- AMRC $20.79
- OCS N/A
- Revenue Growth
- AMRC 22.85
- OCS N/A
- 52 Week Low
- AMRC $8.49
- OCS $10.79
- 52 Week High
- AMRC $39.68
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- AMRC 67.79
- OCS 46.62
- Support Level
- AMRC $22.04
- OCS $17.51
- Resistance Level
- AMRC $22.99
- OCS $18.16
- Average True Range (ATR)
- AMRC 1.73
- OCS 0.36
- MACD
- AMRC 0.30
- OCS 0.01
- Stochastic Oscillator
- AMRC 87.88
- OCS 40.48
About AMRC Ameresco Inc.
Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.